(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Nuvalent's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,102,760,673, with the lowest NUVL revenue forecast at $12,558,280, and the highest NUVL revenue forecast at $3,607,341,091. On average, 19 Wall Street analysts forecast NUVL's revenue for 2027 to be $14,771,348,318, with the lowest NUVL revenue forecast at $3,883,050,913, and the highest NUVL revenue forecast at $30,909,060,113.
In 2028, NUVL is forecast to generate $42,193,744,437 in revenue, with the lowest revenue forecast at $14,954,525,930 and the highest revenue forecast at $90,409,551,150.